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Defective and/or delayed wound healing has been implicated in
the pathogenesis of several chronic inflammatory disorders, in-
cluding inflammatory bowel disease (IBD). The resolution of
inflammation is particularly important in mucosal organs, such as
the gut, where restoration of epithelial barrier function is critical
to reestablish homeostasis with the interfacing microenvironment.
Although IL-33 and its receptor ST2/ILRL1 are known to be in-
creased and associated with IBD, studies using animal models of
colitis to address the mechanism have yielded ambiguous results,
suggesting both pathogenic and protective functions. Unlike those
previously published studies, we focused on the functional role of
IL-33/ST2 during an extended (2-wk) recovery period after initial
challenge in dextran sodium sulfate (DSS)-induced colitic mice. Our
results show that during acute, resolving colitis the normal
function of endogenous IL-33 is protection, and the lack of either
IL-33 or ST2 impedes the overall recovery process, while exoge-
nous IL-33 administration during recovery dramatically accel-
erates epithelial restitution and repair, with concomitant
improvement of colonic inflammation. Mechanistically, we show
that IL-33 stimulates the expression of a network of microRNAs
(miRs) in the Caco2 colonic intestinal epithelial cell (IEC) line, espe-
cially miR-320, which is increased by >16-fold in IECs isolated from
IL-33–treated vs. vehicle-treated DSS colitic mice. Finally, IL-33–
dependent in vitro proliferation and wound closure of Caco-2 IECs
is significantly abrogated after specific inhibition of miR-320A.
Together, our data indicate that during acute, resolving colitis,
IL-33/ST2 plays a crucial role in gut mucosal healing by inducing
epithelial-derived miR-320 that promotes epithelial repair/restitu-
tion and the resolution of inflammation.
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The resolution of inflammation at mucosal surfaces is a fun-damental physiological process that promotes restitution of
the epithelial barrier and appropriate tissue repair in an attempt
to restore normal organ function and homeostatic conditions
with the interfacing microenvironment. Dysfunction and/or delay
in mucosal healing has been implicated in the pathogenesis of
several chronic inflammatory disorders, including psoriasis, idi-
opathic pulmonary fibrosis, and inflammatory bowel disease
(IBD) (1). Crohn’s disease (CD) and ulcerative colitis (UC), two
main forms of IBD, are chronic, relapsing inflammatory disor-
ders of the gastrointestinal (GI) tract resulting from dysregulated
immune responses toward environmental factors in genetically
predisposed individuals. In this setting, achieving efficient reso-
lution of inflammation and mucosal healing is one of the most
important goals to achieve to maintain long-term remission in
patients with IBD.
Although the precise etiology is currently unknown, it is widely
accepted that an imbalance of pro- and antiinflammatory me-
diators is a key mechanism in the pathogenesis of IBD (2);
among these, a wealth of data supports the role of the IL-1
family of cytokines (3). IL-33/IL-1F11 is the most recently
identified member of this family and is widely expressed in var-
ious organs, particularly those positioned at mucosal surfaces,
such as the GI tract (4). The main cellular sources of IL-
33 within the GI tract are predominantly nonhematopoietic in
nature and include intestinal epithelial cells (IECs), endothelial
cells, subepithelial myofibroblasts (SEMFs), and smooth muscle
cells (4–9); however, IL-33 is also expressed in cells of hemato-
poietic origin, particularly professional antigen-presenting cells,
such as macrophages (4, 5). IL-33 serves as a protein with dual
functions that can act both as a classic cytokine and as an
intracellular nuclear factor (4, 10). Similar to IL-1α, IL-33
functions as an endogenous danger signal, or “alarmin,” that is
released from stressed, damaged, or necrotic cells and alerts the
innate immune system to tissue injury during trauma or infection
(11). As a classic signaling cytokine, IL-33 exerts its biological
effects through binding to its cognate receptor, IL-1 receptor-
like 1 (IL1RL1)/IL-1R4, also known as “ST2L,” pairing with its
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coreceptor, IL-1 receptor accessory protein (IL1RAcP)/IL-1R3,
and activating MAPK and NF-κB pathways (4, 12). A secreted,
soluble isoform of ST2 (sST2) also exists, which results from
differential splicing of IL1RL1 and which down-regulates IL-33’s
bioactivity by functioning as an antagonist decoy receptor (13).
Several cell types within the GI tract express ST2, most preva-
lently type 2 innate lymphoid cells, eosinophils, mast cells, al-
ternatively activated M2 macrophages, Th2 lymphocytes, Tregs,
IECs, SEMFs, and adipocytes (4, 5, 14–16). While one of the
first reported and main functions of IL-33 is to promote the
Th2 immune responses (4), IL-33 is now well recognized as
playing a role in several biological functions aside from immune
regulation (17).
The role of the IL-33/ST2 axis in the pathogenesis of IBD was
first reported in 2010, revealing a strong association with UC (5–
8). In subsequent attempts to determine the precise mechanistic
role of IL-33 in IBD, investigations have mainly been performed
using chemically induced mouse models of colitis (SI Appendix,
Table S1). The most commonly used of these is acute adminis-
tration of dextran sodium sulfate (DSS), which has long been
established as an effective model of epithelial damage that re-
sults in a highly reproducible acute colitis with weight loss,
bloody diarrhea, and mucosal ulceration (18). Interestingly, in-
vestigations into the role of IL-33 in the development of colitis
using variations of this model have generated ambiguous results,
revealing both protective and pathogenic functions (SI Appendix,
Table S1). Nevertheless, although DSS-induced colitis does not
recapitulate all features of IBD [e.g., colitis occurs in the absence
of adaptive immune responses that are a hallmark feature of the
human condition (19)], several variations are routinely used to
study different aspects of colitis. In fact, studying the recovery
phase following DSS challenge is a useful approach to specifically
evaluate potential mechanism(s) of epithelial restitution and repair
as well as mucosal healing. Therefore, unlike previously published
studies investigating the role of the IL-33/ST2 axis in DSS-induced
colitis, we focused on an extended 2-wk recovery period after DSS
challenge to mechanistically evaluate how IL-33 and ST2 affect the
resolution of inflammation and mucosal healing.
In the present study we show that, although IL-33 can initially
sustain colonic inflammation in mice immediately after acute
DSS challenge, its primary role is to promote mucosal wound
healing during recovery. In fact, both Il33 and St2 deficiency
considerably dampen epithelial restitution and repair and exac-
erbate ulcer formation up to 2 wk into recovery. Conversely,
exogenous IL-33 administration during recovery is potently ef-
fective in accelerating mucosal healing and decreasing colitis
severity. In vitro studies demonstrate that IL-33 has a direct ef-
fect on the Caco-2human colonic IEC line by inducing cell
proliferation and promoting wound closure. Microarray analysis
of IL-33–stimulated IECs confirmed the activation of intracel-
lular proliferative pathways and showed increased expression of
a network of microRNAs (miRs), of which MIR320A was one of
the most highly expressed. Mechanistically, miR-320A inhibition
in Caco-2 cells significantly decreases IL-33–dependent cell
proliferation and wound closure, while increased Mir320 is ob-
served in IECs isolated from IL-33–treated vs. vehicle-treated
DSS colitic mice. Taken together, our data indicate that during
acute, resolving colitis, the IL-33/ST2 axis plays a critical role in gut
mucosal wound healing by inducing epithelial-derived miR-320,
promoting epithelial repair and restitution, overall restoration of
barrier integrity, and the resolution of inflammation.
Results
IL-33 and Its Receptor ST2 Are Up-Regulated and Localized to the
Epithelium During Recovery from DSS-Induced Colitis. Using a
highly reproducible model of epithelial damage and repair with
extended recovery, we found that colonic Il33 increased dra-
matically (by 4.1 ± 0.2-fold, P < 0.001) in C57BL/6J (B6) mice
(SI Appendix, Fig. S1) immediately after DSS challenge (here-
after, “DSS B6 mice”) compared with control B6 mice admin-
istered regular drinking water and was further augmented (by
5.1 ± 0.5-fold vs. control mice, P < 0.001) after 1-wk recovery
during peak inflammation (Fig. 1A). After 2-wk recovery, when
mucosal healing was evident, Il33 in DSS-induced colitic mice
decreased markedly (by 80.8%, P < 0.001) compared with levels
at 1-wk recovery and was similar to levels in uninflamed con-
trol mice (Fig. 1A). Similar trends were observed for colonic
ST2 mRNA levels in DSS-treated mice (Fig. 1B). Il1rl1 expres-
sion of cell-surface ST2L was elevated after 5 d of DSS admin-
istration (2.4 ± 0.2-fold vs. control mice, P < 0.001) and
increased, reaching peak levels at 1-wk recovery (3.5 ± 0.2-fold
vs. control mice, P < 0.001 and 1.5 ± 0.3-fold vs. 5-d DSS chal-
lenge, P < 0.01). After 2-wk recovery, Il1rl1 (ST2L) was reduced
compared with 1-wk recovery and compared with 5-d DSS
challenge (by 62.8 and 45.9%, respectively, both P < 0.001) and
reached baseline levels close to those of control mice (Fig. 1B,
Left). Similarly, Il1rl1 (sST2) increased at 5-d DSS challenge
(3.3 ± 0.6-fold vs. control mice, P < 0.01), rose further after 1-wk
recovery (5.2 ± 0.9-fold vs. control mice, P < 0.01), and sub-
sequently decreased (by 58.4% vs. 1-wk recovery, P < 0.05) but,
interestingly, remained elevated compared with control mice at
2-wk recovery (2.2 ± 0.6-fold, P < 0.05) (Fig. 1B, Right).
At the protein level (Fig. 1 C and D), while the abundance
of colonic IL-33 and total ST2 remained relatively constant
throughout the experimental period in control mice, both were
considerably increased in colitic mice, reaching peak levels at
1-wk recovery and remaining elevated after 2-wk recovery (P <
0.001 and P < 0.01, respectively, vs. control mice), when epi-
thelial restitution and repair is achieved, eventually decreasing
from 1-wk to 2-wk recovery (P < 0.05) (Fig. 1 C and D, Left).
Western blots for IL-33 showed the presence of 30 and 20–
22 kDa bands, corresponding to full-length (f) IL-33, the most
bioactive form, and cleaved (c)-IL33, a less bioactive isoform
(20), respectively. f-IL-33 was up-regulated in the colons of DSS-
challenged mice compared with control mice, with little post-
translational modification into c-IL-33, which was equally low in
all groups (Fig. 1C, Right). The difference in total ST2 protein
was mainly contributed by sST2 (∼60 kDa), which was the
prevalent form up-regulated in colons of DSS colitic mice, while
cell-surface ST2L (∼120 kDa), the predominant form in control
mice, diminished considerably after 5-d DSS challenge but began
to reappear during recovery (Fig. 1D, Right).
IL-33 and ST2 immunolocalized to colon tissues from both
DSS-treated and control mice, although the intensity and dis-
tribution varied among experimental groups (Fig. 2). In unin-
flamed control mice, IL-33 localized primarily to IECs but also
to lamina propria mononuclear cells (LPMCs), while ST2 was
found mainly in surface IECs (Fig. 2, Left). Following 5-d DSS
challenge and at 1-wk recovery, IL-33 increased dramatically in
inflamed colonic tissues (Fig. 2, Upper Middle), with intense
staining primarily localized to IECs, particularly restituting epi-
thelium (black arrows). ST2 was similarly augmented in inflamed
tissues after 5-d DSS challenge (Fig. 2, Lower Middle) but was
most notably localized to ulcerated lesions and areas of reepi-
thelialization upon recovery and initial reformation of crypts
(Fig. 2, Lower Right).
Overall, these data suggest that IL-33 is potently up-regulated
following acute DSS challenge and also during active recovery;
as such, the overall functional effects of IL-33 and whether its
expression is a consequence of inflammation or healing are still
unclear. However, the potential role of ST2 is better defined.
Total ST2 is also elevated, which functionally likely represents
the observed increase in sST2 in an attempt to decrease the
pathogenic inflammatory activity of IL-33 or, alternatively, up-
regulation of epithelial ST2L to promote IL-33–dependent re-
pair and restitution of barrier integrity.
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Il33−/− and St2−/− Mice Are Deficient in Their Ability to Recover from
Acute DSS-Induced Colitis. To address whether the role of IL-
33 during recovery from DSS-induced colitis is protective or
pathogenic, we performed the same experiment using Il33- and/
or St2-deficient mice (Fig. 3). Il33−/− and St2−/− mice exposed to
DSS (DSS Il33−/− and DSS St2−/− mice, respectively) lost less of
their initial body weight and displayed a decreased disease ac-
tivity index (DAI) than DSS-challenged Il33+/+St2+/+ (DSS WT)
controls early during DSS challenge and after 1-wk recovery
(both P < 0.01), consistent with the observation that early IL-
33 expression appears to possess pathogenic functional effects
(Fig. 3A, Left and Left Center). At 2 wk, however, DSS Il33−/−
and St2−/− mice continued to lose weight and sustained an ele-
vated DAI compared with DSS WT mice (both P < 0.01), which,
like DSS B6 mice (SI Appendix, Fig. S1 A and B), showed effi-
cient recovery as indicated by both weight gain almost back to
baseline and a dramatic drop in DAI (Fig. 3A, Left and Center
Left). Similarly, endoscopic examination of the colonic mucosa
revealed progressive worsening of disease in DSS Il33−/− and
St2−/− mice, peaking at 2-wk recovery (P < 0.05 and P < 0.01,
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Fig. 1. IL-33 and ST2 are modulated, with differential expression of protein isoforms, during acute DSS challenge and recovery from colitis. (A and B) Il33 (A)
and Il1rl1 (B) encoding ST2L (B, Left) and sST2 (B, Right) in colons from DSS B6 mice at baseline/steady state (day 0), after 5 d of DSS challenge, and at 1- and
2-wk recovery (n = 5–7). Vehicle-treated B6 mice served as controls (Cont. B6) and were killed at the same time points as DSS-treated mice. (C and D) IL-33 (C)
and total ST2 (D), evaluated quantitatively (n = 7–8) (Left) and for expression of protein isoforms (Western blots representative of four separate experiments)
(Right) to distinguish between full-length (f)- and cleaved (c)-IL-33, at 30 and 20–22 kDa, respectively (C, Right), and between ST2L (∼120 kDa) and sST2
(∼60 kDa) (D, Right). Either recombinant mouse IL-33 (rmIL) (∼18 kDa) or ST2/IL-33R (∼63 kDa) proteins were used as positive controls. Data are expressed as
mean ± SEM with relative fold differences compared with control B6 mice at 5-d DSS challenge (arbitrarily set as 1); *P < 0.05, **P < 0.01, ***P < 0.001 vs. time
point-matched control B6 mice; §P < 0.05, §§§P < 0.01 vs. 1-wk recovery in DSS B6 mice; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. DSS B6 mice at 5-d DSS challenge.
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Fig. 2. IL-33 and ST2 are predominantly localized to the colonic epithelium during acute DSS challenge and recovery from colitis. Representative photo-
micrographs of colonic tissues stained for IL-33 (Upper Row) and ST2 (Lower Row) show primary localization to IECs in uninflamed (no DSS) 5-d control mice
(Far Left), which is unchanged after 1 and 2 wk of recovery. During DSS challenge and 1 wk of recovery, both IL-33 and ST2 are potently increased, particularly
in restituting epithelium (black arrows) overlying ulcer lesions (Center). After 2 wk of recovery (Far Right), crypt formation becomes more prominent, with IL-
33–responsive, ST2-expressing cells limited to regenerating epithelium (n = 8) (original magnification: 20× + 1.25).
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Fig. 3. Absence of the IL-33/ST2 receptor–ligand pair disrupts the ability to recover effectively from DSS-induced colitis. (A) Body weight, DAI, and endoscopic
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untreated mice not exposed to DSS (gray squares), regardless of genotype, are grouped since no significant differences were observed among groups or with
untreated B6 mice (SI Appendix, Fig. S1). (B) Representative endoscopic images; red arrows indicate frank bleeding, and white arrowheads indicate edema. (C)
Representative photomicrographs of H&E-stained colonic tissues (original magnification: 10× + 1.25); black dashed lines demarcate ulcerated mucosal lesions
(also evident on corresponding endoscopic images), and black arrows indicate reepithelialization and healing of mucosa. (D) Representative photomicro-
graphs of colonic tissues stained for BrdU at 2-wk recovery (original magnification: 40× + 1.25); red arrows indicate actively proliferating BrdU+ cells. For each
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respectively, vs. 5-d DSS challenge) and compared with DSS WT
mice at 2-wk recovery (both P < 0.001) (Fig. 3A, Center Right).
These mice showed persistent bleeding (red arrows) and edema
(white arrowheads), with abundant and large mucosal ulcera-
tions, particularly at 2-wk recovery (Fig. 3B, Bottom Right), while
DSS WT mice displayed improved overall endoscopic scores and
mucosal healing (Fig. 3B, Top Right ).
Histologic analyses confirmed these results: Like DSS B6 mice
(SI Appendix, Fig. S1 A–C), WT mice during DSS challenge
showed severe colitis, which improved progressively over 2-wk
recovery (P < 0.001 vs. 5-d DSS challenge) (Fig. 3A, Right).
Conversely, both Il33−/− and St2−/− mice displayed moderate
colitis during DSS challenge, which did not change significantly
even after 2 wk of recovery (Fig. 3A, Right). In fact, at 1-wk re-
covery, areas of regenerating epithelium (black arrows) overlying
ulcerated inflammatory lesions were present in DSS WT mice
(Fig. 3C, Top Center) but were much less evident in DSS Il33−/−
and St2−/− mice even at 2-wk recovery (Fig. 3C, Bottom Right).
Moreover, BrdU staining showed reduced expression and de-
creased epithelial distribution of proliferating cells in both DSS
Il33−/− and St2−/− mice as compared with WT mice, with no
apparent differences between Il33−/− and St2−/− mice (Fig. 3D).
In addition, mice not exposed to DSS (untreated), independent
of genotype (here, grouped together for Il33−/−, St2−/−, and WT
controls), did not show any significant changes (Fig. 3A) and
were similar to results obtained in (untreated) control B6 mice
(SI Appendix, Fig. S1). Overall, these data indicate that the lack
of either IL-33 or ST2 impedes the overall recovery process after
acute DSS colitis and appears to affect epithelial-specific pro-
liferation and repair.
Exogenous Administration of IL-33 During Recovery After DSS
Challenge Enhances Mucosal Healing and the Resolution of Colitis.
To confirm our results thus far and to test the potential thera-
peutic role of IL-33 in promoting epithelial repair/restitution and
ultimate wound healing, we exogenously administered a phar-
macological dose (33 μg/kg) of recombinant IL-33 (rIL-33)
during the recovery period following acute DSS colitis (Fig. 4A).
IL-33–treated mice showed accelerated recovery from body
weight loss compared with vehicle-treated controls (P < 0.01),
reaching initial baseline levels after 2-wk recovery, and lowered
DAI (P < 0.01), decreasing disease activity almost to zero (Fig.
4B). The general endoscopic appearance of the colonic mucosa
was also dramatically improved upon IL-33 treatment (P <
0.001 at both 1- and 2-wk recovery vs. vehicle-treated controls),
with greater magnitude and efficacy between 1 and 2 wk of re-
covery (Fig. 4C). Less edema (white arrowheads) and bleeding
(red arrows) were observed at 1-wk recovery (Fig. 4C), and in-
creased translucency of the mucosal surface, prominent vascu-
larization, and centralized, tubular-shaped lumens became
evident at 2-wk recovery (Fig. 4D).
Histologic analyses provided further support for the efficacy of
IL-33 treatment in promoting epithelial repair/restitution and
mucosal healing, showing decreased inflammation in treated
DSS-induced colitic mice at 1- or 2-wk recovery (P < 0.001) (Fig.
4E). In particular, the emergence of restituting epithelium (black
arrows), goblet cells, and organized colonic crypts (Fig. 4F,
Lower Row), as well as increased expression of BrdU+ cells (Fig.
4G, red arrows), mainly localized to epithelial crypt cells, was
evident in IL-33–treated colitic mice as compared with untreated
controls after 1- and 2-wk recovery. Taken together, these find-
ings indicate that pharmacologic treatment of DSS-induced
colitic mice with rIL-33 during recovery dramatically acceler-
ates epithelial restitution and repair, with concomitant im-
provement of intestinal inflammation.
IL-33 Directly Induces IEC Proliferation and Wound Healing by Specific
Up-Regulation of miR-320. To mechanistically determine the direct
effects of IL-33 on IECs, we performed a series of in vitro ex-
periments using the colonic Caco-2 IEC line stimulated with
human rIL-33. IL-33–treated Caco-2 cells showed increased
proliferation compared with (untreated) controls in a dose-
dependent manner after both 6 and 12 h, with maximum ef-
fects (21.7% vs. control, P < 0.01) at 6 h using 10 ng/mL IL-33
(Fig. 5A). More dramatic results were observed when measuring
in vitro wound healing, demonstrating that IL-33 accelera-
ted IEC wound closure by 33.1% (P < 0.01 vs. control),
with maximum effects at 24 h (Fig. 5B). Microarray analysis
of IL-33–regulated genes in IECs revealed gene targets primarily
involved in cell-cycle function, cell morphology, cell-to-cell sig-
naling and interaction, and cellular development and mainte-
nance (SI Appendix, Table S2). Among these, a specific network
of highly expressed miRs was identified that are associated with
the activation of intracellular proliferative pathways (SI Appen-
dix, Table S3). To confirm these results, we performed in vitro
experiments that were identical to the previous experiments ex-
cept for miR enrichment. Our results showed that after miR
enrichment, MIR320A was the most highly expressed miR in
colonic IECs stimulated with IL-33 (by 12.58 ± 2.63-fold vs.
controls, P < 0.02) (Fig. 5C). These findings were verified in vivo;
IECs isolated from DSS-induced colitic mice treated with IL-
33 during recovery (Fig. 4A) expressed 16.63 ± 1.42-fold ele-
vatedMir320 after 2 wk than vehicle-treated DSS-induced colitic
mice (P < 0.001) (Fig. 5D).
To determine the functional role of miR-320 in IECs, we
transfected Caco-2 cells with small ssRNA molecules designed
specifically either to inhibit miR-320A (mirVana miR-320A in-
hibitor) or to serve as a negative control (scrambled mirVana).
After stimulation with IL-33, reduced MIR320A was confirmed
after specific inhibition of miR-320A (by 84.8% vs. control, P <
0.01) (Fig. 5E), and IL-33–dependent proliferation was partially,
albeit significantly, blocked, by 35.7% vs. control after 6 h (P <
0.05) and by 32.9% vs. control at 24 h (P < 0.01) (Fig. 5F). More
impressively, specific miR-320A inhibition decreased in vitro
wound closure by 66.4% vs. control after 6 h (P < 0.05) and by
74.5% vs. control at 24 h (P < 0.01) (Fig. 5G). Taken together,
these data indicate that IL-33 has a direct effect on epithelial
proliferation and wound healing that is due, in part, to miR-
320 regulation.
Discussion
While the increased expression of IL-33 and its association with
IBD has been firmly established, dissecting the precise mecha-
nistic role of IL-33 during intestinal inflammation has generated
ambiguous results, suggesting both protective and pathogenic
functions. In the great majority of studies using experimental
models of colitis, healthy immunocompetent mice have been
challenged with 1.5–5% DSS continuously for 5–13 d (in some
cases, DSS exposure was repeated with a 5- to 7-d recovery pe-
riod between cycles), and colitis was evaluated either immedi-
ately without recovery or after a recovery period of up to 7 d (SI
Appendix, Table S1). Under these conditions, IL-33 was gener-
ally shown to have pathogenic effects when colitis was evaluated
without recovery or after up to 7 d of recovery and when acute
DSS was administered (without cycling) at a moderate to high
dose (2–5%). These results are consistent with our observation
that deletion of either Il33 or St2 in mice in which colitis was
induced by 3% DSS (which allowed almost 100% survival) was
effective in decreasing DAI, improving endoscopic appearance
of the colonic mucosa, and dampening overall disease severity
when evaluated either during DSS challenge or after 7 d of re-
covery. Importantly, however, when allowed to recover for an
extended period of 2 wk, DSS Il33−/− and St2−/− mice were de-
ficient in their ability to appropriately restitute epithelium, ab-
rogate mucosal ulcerations, and effectively heal the colonic
mucosa as compared with WT controls. These data suggest that
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in healthy mice, when assaulting factors (e.g., DSS) are removed,
the normal function of endogenously produced IL-33 within the
gut mucosa is protection.
This concept is further supported by our results showing that
exogenous supplementation of rIL-33 at pharmacological doses
during recovery from DSS is able to significantly decrease DAI,
promote ulcer healing, restore normal epithelial architecture,
and globally improve gut mucosal wound healing. This finding
may also account for results from previously published studies in
which IL-33 administered during recovery periods between DSS
cycling, commonly used to produce chronic colitis, demonstrated
protective effects (21, 22). In fact, other studies treating colitis
with exogenous, supraphysiological doses of IL-33 generally
resulted in disease improvement in acute and chronic models
(14, 23). Our results, however, conflict directly with those of
Sedhom et al., (24), who reported that inhibiting the IL-33/
ST2 pathway either by genetic ablation or by treatment with a
specific blocking antibody against ST2 ameliorated colitis in two
models of colitis [i.e., DSS- and 2,4,6-Trinitrobenzenesulfonic
acid (TNBS)-induced] by enhancing mucosal healing. Unlike our
study that allowed recovery for 2 wk after ceasing DSS challenge,
experimental mice in the study by Sedhom et al. were not per-
mitted to recover, and colitis was assessed on the last day of
chemical insult, which may, as in our results, represent a time
point when IL-33–dependent disease activity is still increasing
and colonic inflammation is most severe. As such, treatment with
an anti-ST2 antibody during this time period or performing the
same protocol in ST2-deficient mice would predictably decrease
colitis severity. In the same study, exogenous IL-33 treatment
was shown to exacerbate colitis and decrease effective wound
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healing (24). However, an additional observation to note is that
during and immediately after DSS challenge, lamina propria
enriched with activated innate immune cells is maximally ex-
posed to microbial antigens, since epithelial injury and de-
nudation peak, with loss of ST2L-bearing IECs that then are
unable to respond to IL-33 and promote proliferation and repair.
This concept is further supported by our Western blot data
demonstrating the specific loss of ST2L during DSS challenge.
Interestingly, ST2 was also found to be absent or decreased in
the epithelium of UC and Crohn’s colitis patients but was pre-
sent and increased within LPMCs during active disease (5),
which may explain the skewing toward immune activation (vs.
epithelial-induced repair and protection) that promotes chronic
inflammation such as found in IBD.
In fact, the apparent discrepancies in dissecting the precise
role of IL-33 using variations of DSS colitis, as well as other
acute and chronic models of colitis, may simply be explained by
the fact that DSS colitis in healthy, immunocompetent mice
represents the response of a normal animal to acute intestinal
injury, whereas other models possess genetic and immunologic
abnormalities that predispose these mice to chronic intestinal
inflammation, similar to patients with IBD. Such is the case with
the SAMP1/YitFc (hereafter, “SAMP”) mouse strain, which
possesses multifactorial genetic, immunologic, and regional GI
epithelial barrier defects predisposing these mice to spontane-
ously occurring chronic CD-like ileitis that escalates in severity
over time (25). In SAMP mice, IL-33 has deleterious effects
overall, inducing eosinophil infiltration and activation of patho-
genic Th2 immune responses, resulting in chronic intestinal in-
flammation that is dependent on the gut microbiome (26). In
fact, neutralization of IL-33 with an anti-ST2 antibody in this
model was effective in preventing the massive influx of eosino-
phils into the gut mucosa and decreasing the overall severity of
ileal inflammation when used as either a preventive treatment
before the onset of inflammation or a therapeutic treatment of
established disease. However, although the effect was consistent
and significant, disease severity was reduced by only 30% (26),
which, while reflecting efficient blockade of inflammation, may
also compromise effective IL-33–dependent epithelial restitution/
repair and mucosal healing. This concept of the dichotomous
roles of IL-33 during chronic intestinal inflammation is consis-
tent with other innate-type cytokines, including several members
of the IL-1 family such as IL-1, IL-18, and IL-36, which can possess
both protective and proinflammatory functions, depending upon
the immunological status of the host and/or the type and phase
of the ongoing inflammatory process (3, 27, 28).
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In the present study, transcriptional profiling of the Caco-
2 human colorectal epithelial cell line revealed that IL-33
stimulation resulted in the up-regulation of several miRs, in
particular miR-320A, that have the ability to modify molecular
patterns involved in various functions associated with cell pro-
liferation and cell maintenance (SI Appendix, Table S2). In
general, miRs are small, noncoding RNAs of ∼20–24 nt that
posttranscriptionally repress the expression of target genes (29).
Although the exact function of miRs in human development and
physiology remains largely unknown, differential expression of
given miRs during disease progression suggests that miRs have
an especially crucial role in human pathologic conditions, but
they also have been shown to modulate GI mucosal growth and
repair after injury (30, 31). In fact, several GI-specific miRs are
highly expressed in the intestinal epithelium and are critical for
the maintenance of normal barrier integrity and regulation of
tight junction proteins during disease states (30, 31).
Relevant to our results,MIR320A was shown to be abnormally
expressed in mucosal biopsies from IBD patients, and MIR320A
was decreased in UC patients as compared with uninflamed,
healthy controls (32). These findings were later confirmed in a
pediatric population with early-onset IBD, in which MIR320A
was decreased in inflamed vs. uninflamed colonic biopsies from
both UC and CD patients (33). The latter study further showed
in vitro evidence that NOD2 served as a target for MIR320A,
which negatively regulated its expression, specifically in IECs and
under inflammatory conditions (33). NOD2 encodes a cytosolic
protein receptor that recognizes the bacterial cell wall product
muramyl dipeptide and normally promotes its clearance by ac-
tivating a proinflammatory cascade and/or by autophagy to
maintain normal gut homeostasis. Mutations in NOD2 were the
first and strongest reported genetic associations shown to confer
susceptibility to CD (34, 35), suggesting that carriers of such
mutations have a dysfunction in handling normal bacterial loads.
The aforementioned findings, along with the results from our
current study, pose conceptually interesting possibilities re-
garding the potential role of epithelial-derived miR-320 in the
setting of IBD. First, decreased miR-320 can lead to NOD2
overexpression and amplification of aberrant NOD2-induced
proinflammatory events, influenced by carriage of NOD2 muta-
tions. Alternatively, inherent decreased miR-320 may result in the
inability to achieve appropriate epithelial repair and restitution,
leading to impaired gut mucosal healing. Both processes have the
ability to promote uncontrolled immune responses and impair
effective resolution of inflammation.
At present, the role of IL-33–dependent regulation of miR-
320A during IBD is unknown and is the major focus of ongoing
studies in our laboratory at Department of Pathology, Case
Western Reserve University (CWRU). Although our current
results definitively indicate that in normal, immunocompetent
BL6 mice IL-33 induces increased epithelial miR-320 expression
that promotes epithelial repair/restitution and confers normal
mucosal healing, it has yet to be revealed how this process is
defective in inherently colitis-prone mice and/or in patients with
IBD. In fact, the molecular processes responsible for the control
of miR biogenesis in response to challenge or stress remain
largely unknown and are an area of growing investigation. Based
on our results and prior studies, it is tempting to speculate that
dysfunction of IL-33 as a prototypic alarmin and/or increased
epithelial-specific sequestration of IL-33 may negatively regulate
or repress miR-320 synthesis, since primary processing of all
animal miRs is achieved first in the nucleus, with subsequent,
secondary processing occurring within the cytoplasm. As such,
the elevated levels of IL-33 in both the nuclear and cytoplasmic
compartments of IECs commonly observed in IBD patients (5, 6,
8) would potentially allow increased, and easy, accessibility of IL-
33 to a number of different proteins involved in miR processing
and specifically in miR-320 processing. An alternative hypothesis
to consider is that IL-33 can also function as an intracellular
nuclear factor with potent transcriptional-repressor properties
(10), and in this setting IL-33 may regulate various proteins that
impact miR-320 processing or may affect miR-320 transcription
directly. In both scenarios, IL-33–dependent down-regulation of
miR-320 could be achieved.
Additionally, we cannot rule out the possibility that intestinal
tissue protection may require cooperative action from both hema-
topoietic and stromal cell lineages that could be initiated by rapid
epithelial damage-induced alarmins, such as IL-33. One potential
mechanism involves type 2 innate lymphoid cells (ILC2s), which
have the ability to produce amphiregulin (AREG), an EGF re-
ceptor ligand, in response to IL-33 induced by intestinal injury that
consequently mediates epithelial repair and eventual healing (23).
This process can be further enhanced by IL-33–dependent differ-
entiation of Tregs and tolerogenic CD103+ dendritic cells, initiated
by IEC activation and release of IL-33 and the subsequent pro-
duction of Th2 cytokines, ultimately leading to intestinal mucosal
protection (14–16). As such, IL-33/ST2 may orchestrate an inte-
grated framework involving IECs, intestinal ILC2s, and Tregs
through modulation of miR-320A, AREG, and Th2 cytokines, re-
spectively, with the end goal of promoting gut health.
In summary, the results of the present study indicate that,
upon challenge, the inherent role of endogenous IL-33 within
the gut mucosa is protection, potentially through a mechanism
that augments miR-320 expression, inducing epithelial restitu-
tion and repair and overall epithelial barrier integrity. In the
setting of IBD, particularly during early disease stages, this
process may be defective, leading to impaired healing and ex-
acerbation of colitis into a more chronic and sustained in-
flammatory phenotype. Results from this study also provide the
rationale for the potential therapeutic use of either IL-33 or
miR-320A to obtain optimal gut mucosal wound healing and to
promote the resolution of inflammation.
Materials and Methods
Mice. All experimental mice were bred and maintained under specific
pathogen-free conditions in the Animal Resource Center at Case Western
Reserve University. For a full description, see SI Appendix, Materials and
Methods. All procedures performed were approved by the Institutional
Animal Care and Use Committee at CWRU and followed the American As-
sociation for Laboratory Animal Care guidelines.
Model of DSS-Induced Colitis with Extended Recovery. Induction of colitis was
performed on adult C57BL/6J (B6), Il33−/−, and St2−/− mice and their WT
(Il33+/+St2+/+) littermate controls by 5-d administration of 3% DSS, as pre-
viously described (36), but with an extended 2-wk recovery period. Il33−/−,
St2−/−, and WT mice not exposed to DSS served as untreated controls. In
separate experiments, acute colitis was induced in B6 mice, and these mice
were injected i.p. with either murine rIL-33 (33 μg/kg) or vehicle (PBS) control
during the 2-wk recovery period. For a full description, see SI Appendix,
Materials and Methods.
Colonoscopy.Macroscopic progression of colitis was assessed by endoscopy of
left colon and rectum following a standardized protocol (37). For a full de-
scription, see SI Appendix, Materials and Methods.
Tissue Harvest and Histologic Assessment of Colitis. When mice were killed,
whole colons were taken for analysis and histology. Disease severity was
evaluated as previously described (18, 36). For a full description, see SI Ap-
pendix, Materials and Methods.
Immunohistochemistry. Immunohistochemistry (IHC) was performed as pre-
viously described (5) using specific antibodies against murine IL-33 and ST2,
and in select experiments IHC was performed for BrdU to detect cell pro-
liferation. For a full description, see SI Appendix, Materials and Methods.
ELISA and Western Blot Analysis. IL-33 and ST2 protein levels were quantified
by ELISA and evaluated by Western blots to detect specific IL-33 and
ST2 isoforms as previously described (5). For a full description, see SI Ap-
pendix, Materials and Methods.
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IEC Isolation. Freshly isolated colons from vehicle- and IL-33–treated DSS
colitic mice were harvested and processed as previously described (5, 38). For
a full description, see SI Appendix, Materials and Methods.
Cell Culture and in Vitro Assays. Caco-2 cells (HTB-37; ATCC) were grown to 80%
confluency and were cultured with or without human rIL-33. Cells were collected
after 6 and 24 h and were evaluated for cell proliferation using the XTT Cell
Proliferation Assay Kit (ATCC) and measuring wound closure. For full description,
see SI Appendix, Materials and Methods.
Microarray Analysis. Caco-2 cells were cultured with or without human rIL-33,
and total RNA was prepared as described below. RNA (100 ng/μL) was sub-
mitted to the Case Comprehensive Cancer Center’s Gene Expression and
Genotyping Core at Case Western Reserve University for microarray analysis.
For a full description, see SI Appendix, Materials and Methods.
Total RNA Extraction, miR Enrichment, and qPCR. Total RNA extraction and/or
miR enrichment were performed on tissue homogenates and IEC prepara-
tions, and qPCR was done using specific primers for Il33, Il1rl, MIR320A, and
Mir320. For a full description, see SI Appendix, Materials and Methods.
Inhibition of miR-320A. Single-stranded inhibitor RNA molecules (mirVana
inhibitors), designed to specifically target miR-320A, miR-Let7c (positive
control), or scrambled sequences (negative control), were transfected into
Caco-2 cells. Transfection efficiency was confirmed by qPCR analysis of the
miR-Let7c target gene, HMGA2, in miR-Let7c–targeted Caco-2 cells. For a full
description, see SI Appendix, Materials and Methods.
Statistical Analysis. Statistical analyses were performed using one-way
ANOVA with Bonferroni correction for multiple comparisons and individu-
al t test comparisons adjusted for unequal variance (Welch’s correction),
as appropriate.
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